Summit Therapeutics (SMMT) Net Margin (2019 - 2022)
Summit Therapeutics (SMMT) reported Net Margin of 7700.0% for Q3 2022, down 620275.0% on a YoY basis from N/an in Q3 2021, and down 42.57% quarter-over-quarter from 5400.85% in Q2 2022.
Summit Therapeutics (SMMT) Net Margin (2019 - 2022) Analysis & Trends
Summit Therapeutics has reported Net Margin for 4 years, with the latest figure at 7700.0% in Q3 2022.
- For the quarter ending Q3 2022, Net Margin fell 620275.0% year-over-year to 7700.0%; the trailing twelve-month figure through Jun 2023 stood at 268266.82% (down 26427914.0% YoY), and the FY2022 full-year result was 11174.75%, down 627691.0% from the prior year.
- Net Margin for Q3 2022 stood at 7700.0%, down from 5400.85% in the prior quarter.
- The five-year high for Net Margin was 1497.25% in Q3 2021, with the low at 42835.09% in Q2 2021.
- Historically, Net Margin has averaged 9876.03% across 4 years, with a median of 8281.6% in 2022.
- Annual changes were most pronounced in 2021 — Net Margin plunged 3384744 bps — and 2022, when it surged 3743424 bps.
- Summit Therapeutics' Net Margin stood at 4308.11% in 2019, then plunged by 70 bps to 7319.46% in 2020, then slumped by 48 bps to 10796.41% in 2021, then increased by 29 bps to 7700.0% in 2022.
- The last three Net Margin figures came in at 7700.0% (Q3 2022), 5400.85% (Q2 2022), and 8863.2% (Q1 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 0.82% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Summit Therapeutics | 10.09 Bn | 9.99 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | -7,700.00% |
| Jun 30, 2022 | -5,400.85% |
| Mar 31, 2022 | -8,863.20% |
| Dec 31, 2021 | -10,796.41% |
| Sep 30, 2021 | -1,497.25% |
| Jun 30, 2021 | -42,835.09% |
| Mar 31, 2021 | -9,108.33% |
| Dec 31, 2020 | -7,319.46% |
| Sep 30, 2020 | -9,802.76% |
| Jun 30, 2020 | -8,987.65% |
| Mar 31, 2020 | -1,893.21% |
| Sep 30, 2019 | -4,308.11% |